About Junevity

Junevity utilizes its REWIND platform to identify upstream transcriptional regulators of complex metabolic diseases through analysis of extensive transcriptional data and known pharmacological pathways. The company is developing therapeutics aimed at reversing metabolic diseases that affect over one billion people globally.

```xml <problem> Metabolic diseases affect over one billion people globally and are a leading cause of death. Identifying effective therapeutic targets for these complex diseases is challenging due to the intricate interplay of genetic, environmental, and lifestyle factors. Current approaches often fail to address the upstream transcriptional regulators that drive disease progression. </problem> <solution> Junevity is developing therapeutics aimed at reversing metabolic diseases by targeting upstream transcriptional regulators. The company's REWIND platform analyzes extensive transcriptional data and known pharmacological pathways to identify these key regulators. By focusing on these upstream targets, Junevity aims to develop therapies that can effectively reverse the course of metabolic diseases, similar to the effects of exercise. The REWIND platform leverages innovations in genomics, machine learning, CRISPR, and regulatory biology to discover novel drug targets. </solution> <features> - REWIND discovery platform analyzes billions of transcriptional data points from human metabolic disease. - Identifies novel drug targets in known pharmacological pathways. - Focuses on upstream regulators of complex metabolic disease. - Utilizes genomics, machine learning, CRISPR, and regulatory biology. </features> <target_audience> Junevity's primary focus is on individuals affected by metabolic diseases and the healthcare providers who treat them. </target_audience> ```

What does Junevity do?

Where is Junevity located?

Junevity is based in Oakland, United States.

When was Junevity founded?

Junevity was founded in 2023.

Who founded Junevity?

Junevity was founded by Rob C. and Janine Sengstack.

Rob C. - 2x founder
Janine Sengstack - Co-Founder/CEO

Location

Oakland, United States

Founded

2023

Employees

11 employees

Looking for specific startups?

Try our free semantic startup search

Junevity

Score: 75/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

junevity.com 300+

Founded 2023 – Oakland, United States

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (10+)

Rob C.

2x founder

Janine Sengstack

Co-Founder/CEO

Company Description

Problem

Metabolic diseases affect over one billion people globally and are a leading cause of death. Identifying effective therapeutic targets for these complex diseases is challenging due to the intricate interplay of genetic, environmental, and lifestyle factors. Current approaches often fail to address the upstream transcriptional regulators that drive disease progression.

Solution

Junevity is developing therapeutics aimed at reversing metabolic diseases by targeting upstream transcriptional regulators. The company's REWIND platform analyzes extensive transcriptional data and known pharmacological pathways to identify these key regulators. By focusing on these upstream targets, Junevity aims to develop therapies that can effectively reverse the course of metabolic diseases, similar to the effects of exercise. The REWIND platform leverages innovations in genomics, machine learning, CRISPR, and regulatory biology to discover novel drug targets.

Features

REWIND discovery platform analyzes billions of transcriptional data points from human metabolic disease.

Identifies novel drug targets in known pharmacological pathways.

Focuses on upstream regulators of complex metabolic disease.

Utilizes genomics, machine learning, CRISPR, and regulatory biology.

Target Audience

Junevity's primary focus is on individuals affected by metabolic diseases and the healthcare providers who treat them.